Burleson
Burleson
Burleson, Texas, United States23 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Participants With Diabetic Retinopathy Without Center-Involved Diabetic Macular Edema | Diabetes Complications, cardiovascular disorder, diabetes mellitus, diabetic peripheral angiopathy, diabetic retinopathy, endocrine system disorder, eye disorder, retinal disorder, vascular disorder | Recruiting | Phase 2 / Phase 3 | 2026-10-08 | NCT07592273 | |
| Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) | Neovascular Age-related Macular Degeneration | Recruiting | Phase 3 | 2026-10-08 | NCT07007065 | |
| ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 3 | 2026-10-06 | NCT07173751 | |
| Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial) | Neoplasms by Site, Skin and Connective Tissue Diseases, breast adenocarcinoma, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 3 | 2026-10-01 | NCT00310180 | |
| A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC) | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 3 | 2026-09-28 | NCT07144280 | |
| A Study in Adults With Geographic Atrophy | Geographic Atrophy, eye disorder, macular degeneration, retinal degeneration, retinal disorder | Recruiting | Phase 2 | 2026-09-21 | NCT07606365 | |
| Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine | Headache, Neurologic Manifestations, Pain, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, brain disorder, central nervous system disorder, headache disorder, hypnic headache, migraine disorder, nervous system disorder | Active, not recruiting | Phase 3 | 2026-09-21 | NCT03836040 | |
| A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy | Geographic Atrophy, eye disorder, macular degeneration, retinal degeneration, retinal disorder | Recruiting | Phase 3 | 2026-09-18 | NCT06541704 | |
| A Dose-masked Study of Intravitreal EYE103 in Participants With NVAMD or Macular Edema Following BRVO | Embolism and Thrombosis, Venous Thrombosis, cardiovascular disorder, eye disorder, retinal disorder, retinal vein occlusion, thrombotic disease, vascular disorder | Recruiting | Phase 2 | 2026-09-04 | NCT07205887 | |
| A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56 | wet macular degeneration | Active, not recruiting | Phase 3 | 2026-09-03 | NCT06683742 | |
| Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD) | Neovascular Age-related Macular Degeneration (nAMD) | Active, not recruiting | Phase 1 / Phase 2 | 2026-08-27 | NCT05769153 | |
| A Study of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME | Diabetic Macular Edema (DME) | Active, not recruiting | Phase 2 / Phase 3 | 2026-08-20 | NCT06957080 | |
| RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular Edema (CI-DME) | Diabetes Complications, cardiovascular disorder, diabetes mellitus, diabetic peripheral angiopathy, diabetic retinopathy, endocrine system disorder, eye disorder, retinal disorder, vascular disorder | Active, not recruiting | Phase 2 | 2026-08-19 | NCT04567550 | |
| Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD | Eye Diseases, Hereditary, Metaplasia, Neovascularization, Pathologic, Pathologic Processes, Pathological Conditions, Signs and Symptoms, age-related macular degeneration, choroidal neovascularization, eye disorder, macular degeneration, optic choroid disorder, retinal degeneration, retinal disorder, uveal disorder, wet macular degeneration | Active, not recruiting | Phase 3 | 2026-08-03 | NCT05407636 | |
| A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer | HER2-positive Breast Cancer | Active, not recruiting | Phase 3 | 2026-07-23 | NCT03975647 | |
| Prospective Case Collection Study for New Mammography Technologies | Mammography | Active, not recruiting | Not applicable | 2026-06-22 | NCT05199701 | |
| A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age | DNA Virus Infections, Herpesviridae infectious disease, Infections, Varicella Zoster Virus Infection, chickenpox, viral infectious disease | Recruiting | Phase 3 | 2026-05-29 | NCT06740630 | |
| Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration | Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Sensation Disorders, Signs and Symptoms, blindness (disorder), eye disorder, nervous system disorder, vision disorder, wet macular degeneration | Active, not recruiting | Phase 3 | 2026-05-22 | NCT06856577 | |
| A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK | Wet Age-related Macular Degeneration | Active, not recruiting | Phase 3 | 2026-04-29 | NCT06556368 | |
| Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age | Pneumococcal Immunization | Active, not recruiting | Phase 3 | 2026-02-13 | NCT06824181 | |
| Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma | Active, not recruiting | Phase 3 | 2025-09-18 | NCT05382286 | |
| Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration | Neovascular Age-related Macular Degeneration | Active, not recruiting | Phase 3 | 2025-06-17 | NCT06495918 | |
| Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration | Neovascular Age-Related Macular Degeneration | Active, not recruiting | Phase 3 | 2025-04-18 | NCT06223958 |